{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261797","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.950969+00:00","generated_at":"2026-05-17T00:53:44.189209+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cogent Biosciences reports Q3 net loss $80.9M; cash $390.9M; PEAK, APEX readouts in Nov/Dec 2025","bullets":["Cash, cash equivalents and marketable securities at $390.9M; pro forma cash $430M expected to fund into 2027.","Net loss of $80.9M (Q3 2025) vs $70.6M (Q3 2024); R&D expenses $69.0M.","Phase 3 PEAK (GIST) top-line results expected Nov 2025; APEX (AdvSM) in Dec 2025.","NDA filing for NonAdvSM on track for year-end 2025; Breakthrough Therapy Designation granted for bezuclastinib.","Raised $215.8M net from public offering and $39M from ATM since July 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261797","json":"https://secwatch.observer/filing/0001193125-25-261797.json","markdown":"https://secwatch.observer/filing/0001193125-25-261797.md","text":"https://secwatch.observer/filing/0001193125-25-261797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/0001193125-25-261797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312525261797/cogt-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:53:44.189209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}